Innate Pharma (Euronext Paris: FR0010331421 - IPH): First Patient Treated in the EffiKIR Trial

Mon Dec 17, 2012 2:16am EST

* Reuters is not responsible for the content in this press release.

  MARSEILLE, FRANCE, Dec 17 (Marketwire) -- 
Innate Pharma SA (EURONEXT PARIS: IPH), the innate immunity company
developing first-in-class drugs for cancer and inflammatory diseases,
today announces that the first patient was treated in the EffiKIR trial. 

    EffiKIR is a double-blind placebo-controlled randomized Phase II trial of
IPH2102/BMS-986015 as maintenance treatment in elderly patients with
Acute Myeloid Leukemia (AML) in first complete remission. 

    Herve Brailly, CEO of Innate Pharma, said: "EffiKIR is the first Phase II
trial for IPH2102. This is a great step for Innate Pharma and for the
anti-KIR approach." 

    About EffiKIR (study IPH2102-201):

    The protocol calls for inclusion of 150 patients, randomized into three
arms. Two arms will test single agent IPH2102/BMS-986015 at different
doses and one arm will receive placebo. The primary efficacy endpoint is
leukemia-free survival. Secondary endpoints include safety and overall
survival.

    The rationale of this trial is based on the capacity of activated Natural
Killer (NK) cells to directly kill tumor cells and trigger a broad immune
activation. This rationale is supported by clinical studies showing that
activated NK cells may significantly lower the recurrence of various
hematological malignancies, including AML, following hematopoietic stem
cell transplantation (Ref: Ruggeri et al, Blood, 2007, Giebel et al.,
Blood, 2003, Velardi et al, Science, 2002). 

    This trial is sponsored by Innate Pharma and will be performed in France,
with the participation of the two French clinical cooperative groups,
ALFA (ALFA : Acute Leukemia French Association) and GOELAMS (Groupe
Ouest-Est des Leucemies Aigues et Maladies du Sang - Acute Leukemia and
Blood Diseases West-Est Group), harnessing the research effort of the
French centers qualified to treat patients with AML. 

    About IPH2102/BMS-986015:

    IPH2102/BMS-986015 is a fully human monoclonal antibody blocking
interaction between Killer-cell immunoglobulin-like receptors (KIR) on NK
cells with their ligands. Blocking these receptors facilitates activation
of NK cells and, potentially, destruction of tumor cells by the latter.

    IPH2102/BMS-986015 is licensed to Bristol-Myers Squibb Company (NYSE:
BMY). As part of the agreement between Innate Pharma and Bristol-Myers
Squibb, Bristol-Myers Squibb holds exclusive worldwide rights to develop,
manufacture and commercialize IPH2102/BMS-986015 and related compounds
blocking KIR receptors, for all indications. Under the agreement, Innate
Pharma will conduct the development of IPH2102/BMS-986015 through Phase
II in Acute Myeloid Leukemia ("AML"). 

    IPH2102/BMS-986015 is currently tested in a randomized, double-blind,
placebo-controlled Phase II trial in elderly patients with AML in a
maintenance setting (the EffiKIR trial) and in a Phase I trial in
combination with the anti-PD-1 antibody nivolumab (BMS-936558) in solid
tumors.

    About Innate Pharma:

    Innate Pharma S.A. is a biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and inflammatory diseases. 

    The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate
immunity cells. Its innovative approach has been validated by license
agreements with two major pharmaceutical companies, Novo Nordisk A/S and
Bristol-Myers Squibb.

    Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 81 employees as of
September 30, 2012.

    Learn more about Innate Pharma at www.innate-pharma.com.

    Practical Information about Innate Pharma shares:
 ISIN code:
FR0010331421
 Ticker code: IPH

Disclaimer:
 This press release contains
certain forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these forward-looking
statements are subject to numerous risks and uncertainties, which could
cause actual results to differ materially from those anticipated. For a
discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to
differ from those contained in the forward-looking statements, please
refer to the Risk Factors ("Facteurs de Risque") section of the Document
de Reference prospectus filed with the AMF, which is available on the AMF
website (http://www.amf-france.org) or on Innate Pharma's website
(www.innate-pharma.com).

    This press release and the information contained herein do not constitute
an offer to sell or a solicitation of an offer to buy or subscribe to
shares in Innate Pharma in any country.

    INNATE PHARMA 171212: http://hugin.info/155662/R/1665490/540373.pdf 

    

For additional information, please contact:

Innate Pharma 

Laure-Helene Mercier 
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.com 

ATCG Press

Marielle Bricman
Mob.: +33 (0)6 26 94 18 53
mb@atcg-partners.com 

Copyright 2012, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.